抗体药物复合体市场:技术的成长机会

Antibody-drug Conjugates: Technology Growth Opportunities

出版日期: 2022年12月21日 | 出版商:

Frost & Sullivan | 英文 68 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

本报告提供抗体药物复合体(ADC)市场相关调查，市场概要，以及策略性要务，影响市场的成长促进因素与阻碍因素，成长的机会等资讯。

Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders. The rise in the number of drug approvals has also sparked interest in further developing this technology, with several companies developing solutions for one or more ADC components. The development of technologies is ongoing and will only increase as applications of ADCs increasingly expand into non-oncologic indications.

This study covers several new technologies for the three ADC components (antibody, linker, and payload) and highlights drugs in clinical trials that display potential. It provides an overview of key technology platforms, patents, analytical techniques, and manufacturing developments, covering the various technological advancements that may see adoption in ADC development. It also provides an overview of the stakeholder ecosystem, identifying notable mergers, acquisitions, and partnerships. A detailed account of the funding landscape has also been provided. The study also analyzes the growth drivers and restraints influencing the market and identifies the key growth opportunities emerging from the changes in this space for stakeholders and market players to leverage.

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Antibody-drug Conjugate (ADC) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology

Scope and Segmentation

Research Context and Scope
Segmentation
Growth Drivers
Growth Restraints

Growth Opportunity Analysis

Introduction to ADCs
Clinical Potential of ADCs
ADCs: FDA Approvals
ADC Industry Trends

Technology Snapshot

Incremental Innovations in ADCs
ADC Challenges and Novel Solutions
ADC Challenges and Novel Solutions (continued)
Characteristics of ADC Linkers
Types of Conventional ADC Linkers
Platforms for ADC Linkers
Platforms for ADC Linkers (continued)
Platforms for ADC Linkers (continued)
Platforms for adc Linkers (continued)
ADC Linker Developments
Platforms to Improve adc Conjugation
Platforms to Improve adc Conjugation (continued)
Platforms to Improve adc Conjugation (continued)
Characteristics of a Suitable Antibody for ADCs
Platforms for ADC Antibodies
Platforms for ADC Antibodies (continued)
Antibody Developments for ADC
Characteristics of a Suitable Cytotoxic Payload for an ADC
Platforms for Cytotoxic Payload for an ADC
Platforms for Cytotoxic Payload for an ADC (continued)
Payload Developments for ADCs
Novel Platforms for ADC Delivery

Manufacturing, Analytical Techniques, and Other Factors

Impact on CDMOs
ADC: Analysis Technologies, Challenges, and New Developments
ADC: Clinical Pipeline

Stakeholder Ecosystem

M&As
Partnerships and Collaborations for ADCs
Partnerships and Collaborations for ADCs (continued)
Partnerships and Collaborations for ADCs (continued)
Technology Licensing Deals for ADC Development

Funding Landscape

Funding Analysis
Funding Analysis (continued)
Funding Analysis (continued)

Growth Opportunity Universe

Growth Opportunity 1: Non-oncological Indications
Growth Opportunity 1: Non-oncological Indications (continued)
Growth Opportunity 2: Manufacturing and Supply Chain
Growth Opportunity 2: Manufacturing and Supply Chain (continued)
Growth Opportunity 3: Advancements in Linker Chemistry and Antibodies
Growth Opportunity 3: Advancements in Linker Chemistry and Antibodies (continued)